BRPI0514269A - compostos heterocìclicos como agentes farmacêuticos - Google Patents
compostos heterocìclicos como agentes farmacêuticosInfo
- Publication number
- BRPI0514269A BRPI0514269A BRPI0514269-5A BRPI0514269A BRPI0514269A BR PI0514269 A BRPI0514269 A BR PI0514269A BR PI0514269 A BRPI0514269 A BR PI0514269A BR PI0514269 A BRPI0514269 A BR PI0514269A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical agents
- heterocyclic compounds
- compounds
- receptor activity
- compositions
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 title abstract 2
- 102000005962 receptors Human genes 0.000 abstract 3
- 108020003175 receptors Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60023904P | 2004-08-10 | 2004-08-10 | |
| PCT/US2005/028357 WO2006020680A2 (en) | 2004-08-10 | 2005-08-09 | Heterocyclic compounds as pharmaceutical agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0514269A true BRPI0514269A (pt) | 2008-06-10 |
Family
ID=35908114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0514269-5A BRPI0514269A (pt) | 2004-08-10 | 2005-08-09 | compostos heterocìclicos como agentes farmacêuticos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7902237B2 (https=) |
| EP (1) | EP1776112A4 (https=) |
| JP (1) | JP2008509912A (https=) |
| CN (1) | CN101010078A (https=) |
| AU (1) | AU2005272916A1 (https=) |
| BR (1) | BRPI0514269A (https=) |
| CA (1) | CA2574279A1 (https=) |
| MX (1) | MX2007001539A (https=) |
| WO (1) | WO2006020680A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090156644A1 (en) * | 2005-07-21 | 2009-06-18 | Jacob Westman | Use of thiazole derivatives and analogues in the treatment of cancer |
| DE102007003524A1 (de) * | 2007-01-19 | 2008-09-04 | MEDICE Arzneimittel Pütter GmbH & Co. KG | Arzneimittel zur Behandlung und/oder Prävention von Arteriosklerose |
| WO2008090356A1 (en) * | 2007-01-25 | 2008-07-31 | Betagenon Ab | Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity |
| CN101274918A (zh) * | 2007-03-30 | 2008-10-01 | 中国科学院上海药物研究所 | 一类取代五元杂环化合物,其制备方法和医学用途 |
| WO2010086613A1 (en) | 2009-01-30 | 2010-08-05 | Betagenon Ab | Compounds useful as inhibitors as ampk |
| WO2012106581A1 (en) * | 2011-02-03 | 2012-08-09 | The University Of Chicago | Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction |
| NZ734451A (en) * | 2012-06-19 | 2018-12-21 | Intercept Pharmaceuticals Inc | Preparation, uses and solid forms of obeticholic acid |
| JP6556129B2 (ja) | 2013-08-01 | 2019-08-07 | アメリカ合衆国 | ファルネソイドｘ受容体の阻害剤及び医薬としての使用 |
| SI3043865T1 (sl) | 2013-09-11 | 2021-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B |
| EP2952188A1 (en) * | 2014-06-03 | 2015-12-09 | Universität Bern | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation |
| EP3148541B1 (en) | 2014-05-28 | 2020-09-02 | Universität Bern | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation |
| EP3715348A1 (en) | 2015-03-26 | 2020-09-30 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| TW201741307A (zh) * | 2016-02-22 | 2017-12-01 | 艾洛斯生物製藥公司 | Ｆｘｒ調節劑及其使用方法 |
| WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
| JP2020530477A (ja) * | 2017-08-10 | 2020-10-22 | ザ テキサス エーアンドエム ユニヴァーシティ システム | Ｎｒ４ａ１リガンド、医薬組成物、及び関連する使用方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE523919A (https=) * | 1952-10-31 | |||
| US2719162A (en) * | 1954-03-29 | 1955-09-27 | Eastman Kodak Co | 5-(3-hydroxybenzylidene)-3-phenyl-2-phenylimino-4-thiazolidone and process |
| US3097100A (en) * | 1960-01-25 | 1963-07-09 | Eastman Kodak Co | Thiazolidones as light stabilizers for plastic compositions |
| BE608790A (fr) | 1960-10-08 | 1962-04-03 | Kalle Ag | Matériel photosensible. |
| US3314794A (en) | 1964-05-13 | 1967-04-18 | Eastman Kodak Co | Ultraviolet absorbers |
| FR1604530A (https=) * | 1967-06-06 | 1971-11-29 | ||
| US5198454A (en) * | 1991-12-03 | 1993-03-30 | Texas A&M University System | Use of OB-104 to treat ocular inflammation |
| JPH06128234A (ja) | 1992-10-19 | 1994-05-10 | Fuji Photo Film Co Ltd | 不斉炭素原子を有する化合物およびそれからなる非線形光学材料 |
| JP3871354B2 (ja) * | 1994-07-29 | 2007-01-24 | 株式会社フジモト・コーポレーション | 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体 |
| US6353006B1 (en) * | 1999-01-14 | 2002-03-05 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| ES2367539T3 (es) * | 2001-12-21 | 2011-11-04 | X-Ceptor Therapeutics, Inc. | Moduladores heterocíclicos de receptores nucleares. |
-
2005
- 2005-08-09 MX MX2007001539A patent/MX2007001539A/es not_active Application Discontinuation
- 2005-08-09 EP EP05786284A patent/EP1776112A4/en not_active Withdrawn
- 2005-08-09 BR BRPI0514269-5A patent/BRPI0514269A/pt not_active IP Right Cessation
- 2005-08-09 CA CA002574279A patent/CA2574279A1/en not_active Abandoned
- 2005-08-09 CN CNA2005800272537A patent/CN101010078A/zh active Pending
- 2005-08-09 JP JP2007525749A patent/JP2008509912A/ja active Pending
- 2005-08-09 US US11/573,614 patent/US7902237B2/en not_active Expired - Fee Related
- 2005-08-09 AU AU2005272916A patent/AU2005272916A1/en not_active Abandoned
- 2005-08-09 WO PCT/US2005/028357 patent/WO2006020680A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1776112A4 (en) | 2009-11-25 |
| WO2006020680A2 (en) | 2006-02-23 |
| US7902237B2 (en) | 2011-03-08 |
| US20080132519A1 (en) | 2008-06-05 |
| EP1776112A2 (en) | 2007-04-25 |
| CA2574279A1 (en) | 2006-02-23 |
| MX2007001539A (es) | 2007-04-23 |
| CN101010078A (zh) | 2007-08-01 |
| AU2005272916A1 (en) | 2006-02-23 |
| JP2008509912A (ja) | 2008-04-03 |
| WO2006020680A3 (en) | 2006-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0513677A (pt) | derivados de pirrol com agentes farmacêuticos | |
| BRPI0417260A (pt) | derivados de azepinoindol como agentes farmacêuticos | |
| BRPI0412262A (pt) | derivados de azepina como agentes farmacêuticos | |
| BRPI0514269A (pt) | compostos heterocìclicos como agentes farmacêuticos | |
| TW200745124A (en) | Azepinoindole derivatives as pharmaceutical agents | |
| ATE547420T1 (de) | Azepinoindol und pyridoindolderivate als pharmazeutische mittel | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| BRPI0417820A (pt) | heterociclos azabicìclicos como moduladores de receptor canabinóide | |
| EA200800100A1 (ru) | Соединения азаиндазола и способы применения | |
| ECSP10010042A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
| BRPI0511139A (pt) | compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| NO20084712L (no) | Nye farmasoytiske forbindelser | |
| EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| BRPI0512352A (pt) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas | |
| ATE461923T1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
| BRPI0610090A2 (pt) | terapia de combinaÇço compreendendo diaril urÉias para tratar doenÇas | |
| WO2011116161A3 (en) | Arylsulfonamide ccr3 antagonists | |
| BRPI0516883A (pt) | compostos e métodos para modulação da atividade de trombopoietina | |
| TW200733961A (en) | Diaryl urea for treating pulmonary hypertension | |
| UA108073C2 (ru) | 2,5-дизамещенные арилсульфонамидные антагонисты ccr3 | |
| DOP2007000073A (es) | Compuestos para tratar la hipertensión pulmonar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014. |